Calando Pharmaceuticals, an siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation has announced the publication of a study demonstrating the anti-proliferative ...
Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corporation has provided more detail on its product and business goals for 2007. "We have made considerable progress ...
Calando recently proved systemic siRNA delivery and RNAi-mediated mRNA knockdown. Arrowhead Research has increased its ownership of majority-owned subsidiary Calando Pharmaceuticals through the ...
Arrowhead Subsidiary Calando Pharmaceuticals Enters into License Agreement with Cerulean Pharma Inc.
Arrowhead Subsidiary Calando Pharmaceuticals Enters into License Agreement with Cerulean Pharma Inc. - Calando To License Cyclosert TM Platform and Associated IT-101 Drug Candidate for Upfront Payment ...
Calando Pharmaceuticals, a subsidiary of Arrowhead Research, has struck a licensing deal with Cerulean Pharma for Calando's drug delivery platform, Cyclosert, and the associated clinical stage ...
WHEN EXECUTIVES from Calando Pharmaceuticals met with the management team of Agilent Technologies' nucleic acid solutions division, the chemistry was obvious, says John Petrovich, Calando's chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results